Plaid Semiconductors is building a next-generation hardware platform that fits the computing power of an entire data center rack onto a single substrate.

This breakthrough delivers unprecedented performance in compute density, bandwidth, and energy efficiency—far beyond today’s semiconductor technologies.

Mobius AI, Inc. orchestrates certainty in an uncertain world.

We are building the operating system for digital orchestration of the physical world—starting with mobility and non-emergency medical transportation (NEMT).

Atomistic Insights uses physics-based AI to reveal how proteins move and uncover hidden binding sites, enabling faster discovery of more effective medicines.

Neurodiverse Technologies develops adaptive, research-driven simulation platforms that empower neurodivergent individuals to build real-world readiness and confidence.

Our products—including SANDI for driver readiness and NAVIS for interview and employment preparation—combine neuroscience, virtual reality, and machine learning to create accessible, data-informed training environments.

As a Vanderbilt University spin-off, we bridge academic innovation and real-world impact, helping individuals gain independence while enabling institutions to deliver evidence-based readiness programs at scale.

PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions. 
 

At Myosin Therapeutics, we’re tackling aggressive, treatment-resistant cancers by targeting a completely new frontier in cancer biology—the molecular nanomotors that power cancer cell movement, invasion, and survival.

Moonlight Therapeutics is a clinical-stage biotech company developing MOON101, a novel microneedle stamp treatment for peanut allergy that delivers allergen proteins directly into the skin to safely desensitize the immune system.

SelSym Biotech is pioneering hemostasis with SymClot, an innovative platelet-mimetic therapy that promises to dramatically improve patient survival and outcomes by rapidly stopping bleeding after severe trauma and high-risk surgeries.